TMO US EQUITY Health Care Life Sciences Tools & Services CIK: 97745

Thermo Fisher Scientific (TMO) Quant Factor Diagnostic & Fair Value Model

Thermo Fisher Scientific (Ticker: TMO) is listed in the Health Care sector (Life Sciences Tools & Services). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.

$673.82

-0.40% Latest Close (2026-10-23)

Market Cap: $249.14B

P/E Ratio: 36.0

Momentum Strength 3M / 12M

+20.43%

1M: -0.67% 12M: +18.80%

Quality (ROE) Point-in-Time

+7.08%

Trailing Return on Equity

Technical Trend RSI 14

48.9

SMA50: $644.96 SMA200: $549.28

Valuation Multiplier Trailing

36.0

Premium Multiple (> 30x P/E)

📊 Valuation & Multi-Factor Diagnostic

Premium Multiple (> 30x P/E)

TMO trades at 36.0x P/E, reflecting market-implied growth expectations for forward revenue and cash flow.

Compare in Screener

⚡ Benchmark Factor Strategy

S&P 500 Momentum Alpha Strategy

This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.

Strategy Marketplace Open Strategy →

📈 Daily Candlestick & Volume Quant Chart

Interactive lightweight price action & volume breakdown over recent 90 trading days.

均线多头 (MA20/50) Piotroski F-Score: 8/9 (High Financial Strength)

Official Point-in-Time Financial Filing History

Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.

备案 CIK: 97745 · 10-K 年报 / 10-Q 季报

Form	Period End	Filing Timestamp (Point-in-Time)	Revenue	Net Income	Operating CF	EPS (Diluted)
10-Q	2026-06-27	2026-07-31	-	$1.74B	$3.32B	$4.68
10-Q	2025-12-31	2026-07-31	-	-	-	-
10-Q	2025-06-28	2026-07-31	-	$1.62B	$2.12B	$4.28
10-Q	2026-03-28	2026-05-01	-	$1.65B	$1.19B	$4.43
10-Q	2025-03-29	2026-05-01	-	$1.51B	$723.00M	$3.98
10-K	2025-12-31	2026-02-26	-	$6.70B	$7.82B	$17.74
10-K	2024-12-31	2026-02-26	-	$6.33B	$8.67B	$16.53
10-K	2023-12-31	2026-02-26	-	$6.00B	$8.41B	$15.45

💡 Methodology & Frequently Asked Questions

Key reference details regarding Thermo Fisher Scientific (TMO) valuation multiples, momentum factors, and point-in-time filing conventions.

How should TMO's current valuation multiple be interpreted? ↓

TMO trades at a trailing P/E of 36.0x within the Health Care sector (premium multiple (> 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.

What are TMO's key momentum and technical factor indicators? ↓

As of the latest close, TMO shows a 1-month return of -0.67%, 3-month return of +20.43%, and 12-month return of +18.80%, with a 14-day RSI of 48.9. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.

What is Point-in-Time (PIT) financial data and why does it matter for TMO? ↓

Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.

How can TMO be incorporated into systematic factor models? ↓

TMO can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.